This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization for Chinese patients with myasthenia gravis (MG). This study will enroll patients with MG as diagnosed by physician. Approximately 1,200 MG patients are intended to be recruited from approximately 40 sites across majority of regions in China. The clinical and PROs included MGFA class, MGFA PIS, MG-ADL (Activities of Daily Living), QMG (Quantitative MG score), MG QOL-15R, EQ-5D etc. All MG patients enrolled will be followed up every 6 months until end of 2027.
Eligibility
Sex
ALL
Min age
0 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
This study will enroll patients of all ages who are diagnosed with MG of all MGFA classifications by physicians.
1. Patients must have the following data to be enrolled in this study:
* MGFA classification
* MG-ADL score
2. MG patients or their legal guardians/representatives are able to sign the Informed Consent Form (ICF).
Exclusion Criteria:
1. Patients aged ≥18 years with ocular myasthenia gravis (MGFA class I) lasting for more than 2 years;
2. Patients who are currently participating in an interventional clinical trial cannot be enrolled in this study.
Primary outcome measure(s)
Clinical outcome — Every 6 months up to 3 years MGFA classification (e.g I, II, III, IV, V)
Treatment method — Every 6 months up to 3 years Targeted treatment methods (list of methods, including medication, immunoglobulin, plasma exchange, surgery etc. )
Patient-reported outcome — Every 6 months up to 3 years MG-Activities of Daily Living (MG-ADL, aggregated value in a scale, ranged 0- best to 24- worst)
Clinical outcome — Every 6 months up to 3 years MGFA Post-intervention Status (e.g. CSR, PR, MM)
Clinical outcome — Every 6 months up to 3 years Quantitative MG score (QMG, aggregated value in a scale, ranged 0- best to 39-worst)
Clinical outcome — Every 6 months up to 3 years Physician-reported MG crisis
Clinical outcome — Every 6 months up to 3 years Death
Patient-reported outcome — Every 6 months up to 3 years MG-Quality of Life 15-Revised (MG-QoL15-r, aggregated value in a scale for quality of life, ranged 0- best to 60- worst)
Patient-reported outcome — Every 6 months up to 3 years EuroQol-5D (separate value for five dimensions in a scale for quality of life)
Treatment duration — Every 6 months up to 3 years Therapies start and end date
Treatment dose — Every 6 months up to 3 years Dose (e.g. mg)
Treatment frequency — Every 6 months up to 3 years Frequency (e.g. times/day)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.